Anti-CYTC/ CST3/ ARMD11 monoclonal antibody
Anti-CYTC/ CST3/ ARMD11 antibody for FACS & in-vivo assay
Go to CST3/CST3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-MP0338-Ab-1/ GM-Tg-hg-MP0338-Ab-2 | Anti-Human CST3 monoclonal antibody | Human |
GM-Tg-rg-MP0338-Ab-1/ GM-Tg-rg-MP0338-Ab-2 | Anti-Rat CST3 monoclonal antibody | Rat |
GM-Tg-mg-MP0338-Ab-1/ GM-Tg-mg-MP0338-Ab-2 | Anti-Mouse CST3 monoclonal antibody | Mouse |
GM-Tg-cynog-MP0338-Ab-1/ GM-Tg-cynog-MP0338-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CST3 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-MP0338-Ab-1/ GM-Tg-felg-MP0338-Ab-2 | Anti-Feline CST3 monoclonal antibody | Feline |
GM-Tg-cang-MP0338-Ab-1/ GM-Tg-cang-MP0338-Ab-2 | Anti-Canine CST3 monoclonal antibody | Canine |
GM-Tg-bovg-MP0338-Ab-1/ GM-Tg-bovg-MP0338-Ab-2 | Anti-Bovine CST3 monoclonal antibody | Bovine |
GM-Tg-equg-MP0338-Ab-1/ GM-Tg-equg-MP0338-Ab-2 | Anti-Equine CST3 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-MP0338-Ab-1/ GM-Tg-hg-MP0338-Ab-2; GM-Tg-rg-MP0338-Ab-1/ GM-Tg-rg-MP0338-Ab-2; GM-Tg-mg-MP0338-Ab-1/ GM-Tg-mg-MP0338-Ab-2; GM-Tg-cynog-MP0338-Ab-1/ GM-Tg-cynog-MP0338-Ab-2; GM-Tg-felg-MP0338-Ab-1/ GM-Tg-felg-MP0338-Ab-2; GM-Tg-cang-MP0338-Ab-1/ GM-Tg-cang-MP0338-Ab-2; GM-Tg-bovg-MP0338-Ab-1/ GM-Tg-bovg-MP0338-Ab-2; GM-Tg-equg-MP0338-Ab-1/ GM-Tg-equg-MP0338-Ab-2 |
Products Name | Anti-CST3 monoclonal antibody |
Format | mab |
Target Name | CST3 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Diagnostic target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-CST3 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species CYTC/ CST3/ ARMD11 VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | vGMLP002896 | human CST3 Lentivirus particle |
ORF Viral Vector | pGMLP002896 | human CST3 Lentivirus plasmid |
ORF Viral Vector | pGMLV000153 | mouse Cst3 Lentivirus plasmid |
ORF Viral Vector | vGMLV000153 | mouse Cst3 Lentivirus particle |
Target information
Target ID | GM-MP0338 |
Target Name | CST3 |
Gene ID | 1471,13010,574313,100058494 |
Gene Symbol and Synonyms | ARMD11,CST3,CysC,HEL-S-2 |
Uniprot Accession | P01034,O19092 |
Uniprot Entry Name | CYTC_HUMAN,CYTC_MACMU |
Protein Sub-location | Transmembrane Protein |
Category | Diagnostics Biomarker |
Disease | carcinoma, Diabetic Nephropathy, Nephrotoxicity, Sjogren's syndrome salivary, Perinatal necrotizing enterocolitis, Acute kidney failure, Asphyxia neonatorum, Dent disease, Metabolic syndrome, Nephropathy induced by heavy metals, Renal fibrosis |
Gene Ensembl | ENSG00000101439 |
Target Classification | N/A |
The target: CST3, gene name: CST3, also named as ARMD11, HEL-S-2. The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences. Some of the members are active cysteine protease inhibitors, while others have lost or perhaps never acquired this inhibitory activity. There are three inhibitory families in the superfamily, including the type 1 cystatins (stefins), type 2 cystatins and the kininogens. The type 2 cystatin proteins are a class of cysteine proteinase inhibitors found in a variety of human fluids and secretions, where they appear to provide protective functions. The cystatin locus on chromosome 20 contains the majority of the type 2 cystatin genes and pseudogenes. This gene is located in the cystatin locus and encodes the most abundant extracellular inhibitor of cysteine proteases, which is found in high concentrations in biological fluids and is expressed in virtually all organs of the body. A mutation in this gene has been associated with amyloid angiopathy. Expression of this protein in vascular wall smooth muscle cells is severely reduced in both atherosclerotic and aneurysmal aortic lesions, establishing its role in vascular disease. In addition, this protein has been shown to have an antimicrobial function, inhibiting the replication of herpes simplex virus. Alternative splicing results in multiple transcript variants encoding a single protein. [provided by RefSeq, Nov 2014].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.